Among these novel therapies, researchers in the field of HNSCC, including OPSCC, start to explore the effect of IDO1 inhibition therapy and toll-like receptor 8 (TLR8) agonists therapy through clinical trials. The gene discussed is IDO1; the disease is head and neck squamous cell carcinoma.